Drugs / SCT200
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT05552807 | Jun 2022 → Sep 2023 | head and neck squamous cell carcinoma | Sinocelltech Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04229537 | Mar 2020 → Aug 2022 | colorectal cancer, esophageal squamous cell carcinoma | Sinocelltech Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03808701 | Mar → Dec 2019 | non-small cell squamous lung carcinoma | Sinocelltech Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03692520 | Sep 2018 → Nov 2019 | cancer | Sinocelltech Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT02211443 | Jan → Dec 2015 | colorectal cancer | Sinocelltech Ltd. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03817567 | Jul 2018 → Nov 2019 | esophageal squamous cell carcinoma | Sinocelltech Ltd. | Unknown | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT03874741 | May 2019 → Jun 2020 | head and neck squamous cell carcinoma | Sinocelltech Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT03744208 | Dec 2018 → Dec 2019 | head and neck squamous cell carcinoma | Shi Yuankai | Unknown | No outcome recorded |
| Phase 2 | NCT03713372 | Nov 2018 → Feb 2020 | head and neck cancer | Sinocelltech Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT03692689 | Jul 2018 → Sep 2019 | triple-negative breast carcinoma | Sinocelltech Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT03405272 | Feb → Dec 2018 | colorectal cancer | Sinocelltech Ltd. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCT200 | “The purpose of this study is to evaluate the efficacy and safety of first-line with recombinant anti-EGFR monoclonal antibody（SCT200）and standard chemotherapy in patients with...” NCT03744208 ↗10“Experimental: Recombinant Anti-EGFR Monoclonal Antibody（SCT200）. Initially, SCT200 6.0mg/kg will be administered at day 1 every week for a maximum of 6 cycles.” NCT03817567 ↗ “Initially, 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles.” NCT03713372 ↗ “SCT200 is a newly developed recombinant, fully humanized, anti-EGFR monoclonal antibody.” PMID 36307775 ↗ Oct 2022 |
| Action | Inhibit | “anti-EGFR” NCT03808701 ↗ |
| Modality | Monoclonal antibody | “SCT200 is a newly developed recombinant, fully humanized, anti-EGFR monoclonal antibody.” PMID 36307775 ↗ Oct 2022 |
| Route | Intravenous | “SCT200 was administrated intravenously” PMID 36307775 ↗ Oct 2022 |
| Target | EGFR | “SCT200 is a newly developed recombinant, fully humanized, anti-EGFR monoclonal antibody.” PMID 36307775 ↗ Oct 2022 |